Issue 44, 2015

An integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: synthesis and photoactivation studies

Abstract

A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing αVβ3 integrin compared to control DU-145 human prostate carcinoma cells.

Graphical abstract: An integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: synthesis and photoactivation studies

Supplementary files

Article information

Article type
Communication
Submitted
16 Apr 2015
Accepted
23 Apr 2015
First published
28 Apr 2015
This article is Open Access
Creative Commons BY license

Chem. Commun., 2015,51, 9169-9172

Author version available

An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies

A. Gandioso, E. Shaili, A. Massaguer, G. Artigas, A. González-Cantó, J. A. Woods, P. J. Sadler and V. Marchán, Chem. Commun., 2015, 51, 9169 DOI: 10.1039/C5CC03180J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements